Published May 16, 2022 | Version 5.7
Journal article Open

HFE H63D mutation: why are you killing your patients?

Description

Evidence-based medicine has shown for many years that homozygous mutations of the HFE gene H63D are by no means negligible. Not only can it cause, usually after a second hit, rather mild classical hemochromatosis, but it can also cause numerous other disorders of iron metabolism, such as hypotransferrinemia, changes in binding capacity, and others. In addition, it may lead - among other symptoms - to damages of the heart and the substantia nigra via a causal relationship that remains to be investigated, most likely via a cascade dysfunction in iron metabolism. The clinical facts are compelling. Any physician who dismisses mutations of the HFE gene H63D as clinically irrelevant risks the health and life of his patient. We report two patients with an HFE H63D mutation who were treated almost two decades too late because of outdated expertise.

Notes

Peer review completed, August 12th, 2022. Responsible: Team III (Dr. Kramer) of Swabian Research & Publishing (www.swabian.org)

Files

ignoring h63d is fatal.pdf

Files (350.1 kB)

Name Size Download all
md5:e71c9780fc9ffe5ea223fba2ea7390cf
350.1 kB Preview Download